Nextcure Stock Today
| NXTC Stock | USD 1.35 0.04 3.05% |
Performance0 of 100
| Odds Of DistressOver 59
|
NextCure is trading at 1.35 as of the 8th of October 2024, a 3.05 percent increase since the beginning of the trading day. The stock's open price was 1.31. NextCure has over 59 % chance of experiencing financial distress in the next 2 years of operation and has generated negative returns for investors over the last 90 days. Equity ratings for NextCure are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 8th of September 2024 and ending today, the 8th of October 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 9th of May 2019 | Category Healthcare | Classification Health Care |
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland. The company has 27.98 M outstanding shares of which 65.81 K shares are now shorted by private and institutional investors with about 2.75 trading days to cover. More on NextCure
Moving against NextCure Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
NextCure Stock Highlights
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Health Care, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsNextCure can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand NextCure's financial leverage. It provides some insight into what part of NextCure's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
NextCure (NXTC) is traded on NASDAQ Exchange in USA. It is located in 9000 Virginia Manor Road, Beltsville, MD, United States, 20705 and employs 82 people. NextCure is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 37.77 M. NextCure conducts business under Biotechnology sector and is part of Health Care industry. The entity has 27.98 M outstanding shares of which 65.81 K shares are now shorted by private and institutional investors with about 2.75 trading days to cover.
NextCure currently holds about 185.49 M in cash with (52.97 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.68, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check NextCure Probability Of Bankruptcy
Ownership AllocationNextCure maintains a total of 27.98 Million outstanding shares. Over half of NextCure's outstanding shares are owned by institutional investors. These institutional investors are typically referred to as corporate investors that shop for positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check NextCure Ownership Details
NextCure Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Federated Hermes Inc | 2024-06-30 | 327.4 K | |
| Acuitas Investments, Llc | 2024-06-30 | 323.3 K | |
| Citadel Advisors Llc | 2024-06-30 | 289.1 K | |
| Bml Capital Management Llc | 2024-06-30 | 276.5 K | |
| Cardiff Park Advisors, Llc | 2024-06-30 | 262 K | |
| Hudson Bay Capital Management Lp | 2024-06-30 | 203.8 K | |
| Geode Capital Management, Llc | 2024-06-30 | 195.9 K | |
| Assenagon Asset Management Sa | 2024-06-30 | 184.5 K | |
| Macquarie Group Ltd | 2024-06-30 | 150 K | |
| Logos Global Management Lp | 2024-06-30 | 5 M | |
| Sofinnova Ventures | 2024-06-30 | 2.7 M |
NextCure Historical Income Statement
NextCure Stock Against Markets
NextCure Corporate Management
| CPA CPA | Chief Officer | Profile | |
| Steven CPA | Chief Officer | Profile | |
| Sebastien Maloveste | Senior Development | Profile | |
| Sourav Kundu | Senior Manufacturing | Profile | |
| Kevin Shaw | General Counsel | Profile | |
| Michael MSBA | CEO, CoFounder | Profile | |
| Lieping MD | CoFounder Board | Profile |
Additional Information and Resources on Investing in NextCure Stock
When determining whether NextCure offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of NextCure's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Nextcure Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Nextcure Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NextCure. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For information on how to trade NextCure Stock refer to our How to Trade NextCure Stock guide.You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NextCure. If investors know NextCure will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NextCure listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.19) | Quarterly Revenue Growth (1.00) | Return On Assets (0.31) | Return On Equity (0.55) |
The market value of NextCure is measured differently than its book value, which is the value of NextCure that is recorded on the company's balance sheet. Investors also form their own opinion of NextCure's value that differs from its market value or its book value, called intrinsic value, which is NextCure's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NextCure's market value can be influenced by many factors that don't directly affect NextCure's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NextCure's value and its price as these two are different measures arrived at by different means. Investors typically determine if NextCure is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NextCure's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.